Cargando…
Meta-analysis of Shugan Jieyu Capsule for depression in patients with coronary heart disease
INTRODUCTION: Shugan Jieyu Capsule (SGJYC) has been prescribed to treat primary and secondary depression; however, whether it can benefit depression of patients with coronary heart disease (CHD) remains controversial. This meta-analysis aimed to evaluate the efficacy and safety of SGJYC in treating...
Autores principales: | Liu, Zhen, Gu, Chunhua, Lei, Jian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10470748/ https://www.ncbi.nlm.nih.gov/pubmed/37653746 http://dx.doi.org/10.1097/MD.0000000000034685 |
Ejemplares similares
-
Efficacy and safety of Shugan Jieyu Decoction in the treatment of coronary heart disease complicated with depression
por: Li, Zhenzhen, et al.
Publicado: (2023) -
Efficacy and safety of Shugan Jieyu capsule in the treatment of essential hypertension with insomnia, anxiety or depression: A protocol for systematic review and meta-analysis
por: Fan, Maoxia, et al.
Publicado: (2021) -
Shugan Jieyu Capsule in Post-Stroke Depression Treatment: From Molecules to Systems
por: Zhang, Meng, et al.
Publicado: (2022) -
Improved Resting-State Functional Dynamics in Post-stroke Depressive Patients After Shugan Jieyu Capsule Treatment
por: Yao, Guanqun, et al.
Publicado: (2020) -
Effectiveness of the Shugan Jieyu Capsule against Psychiatric Symptoms in Epilepsy: a protocol for systematic review and meta-analysis
por: Kim, Sejin, et al.
Publicado: (2023)